6-Panel Drug Test (Any combination) + Alcohol (Strip) (DTS331)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Sample
urine
Intended Use
The CD DOA/Alcohol Rapid Test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of drug substances in human urine specimens. This assay may be used in the point of care setting. Below is a list of cut-off concentrations for each drug.
Storage
The DOA/Alcohol Rapid Test Device should be stored at 4 to 30°C and will be effective until the expiration date stated on the package. The product is humidity-sensitive and should be used immediately after being open. Any improperly sealed product should
Sensitivity
The cut-off concentrations (sensitivity level) of the DOA/Alcohol Rapid Test Device are determined to be: AMP 1000 ng/ml, BAR, 300 ng/ml, BZO 300 ng/ml, BUP 10 ng/ml, COC 300 ng/ml, EDDP 100 ng/ml, KET 1000 ng/ml, MTD 300 ng/ml, MET 1000 ng/ml, MDMA 500 ng/ml, OPI 300 ng/ml, OPI II 2000 ng/ml, OXY 100 ng/ml, PCP 25 ng/ml , PPX 300 ng/ml, THC 50 ng/ml, 200ng/ml of TRA and TCA 1000 ng/ml.

Citations


Have you cited DTS331 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi

JOURNAL OF CLINICAL MEDICINE

Authors: Ciza, Francois; Gils, Tinne; Sawadogo, Michel; Decroo, Tom; Roggi, Alberto; Piubello, Alberto; Ortuno-Gutierrez, Nimer

The introduction of the nine-month short-treatment regimen (STR) has drastically improved outcomes of rifampicin-resistant tuberculosis (RR-TB) treatment. Adverse events (AE) commonly occur, including injectable-induced hearing loss. In Burundi we retrospectively assessed the frequency of adverse events and treatment modifications in all patients who initiated the STR between 2013-2017. Among 225 included patients, 93% were successfully treated without relapse, 5% died, 1% was lost-to-follow-up, 0.4% had treatment failure and 0.4% relapsed after completion. AE were reported in 53%, with grade 3 or 4 AE in 4% of patients. AE occurred after a median of two months. Hepatotoxicity (31%), gastro-intestinal toxicity (22%) and ototoxicity (10%) were most commonly reported. One patient suffered severe hearing loss. Following AE, 7% of patients had a dose reduction and 1% a drug interruption. Kanamycin-induced ototoxicity led to 94% of modifications. All 18 patients with a modified regimen were cured relapse-free. In this exhaustive national RR-TB cohort, RR-TB was treated successfully with the STR. Adverse events were infrequent. To replace the present STR, all-oral regimens should be at least as effective and also less toxic. During and after transition, monitoring, management, and documentation of AE will remain essential.

In vitro evaluation of bone cements impregnated with selenium nanoparticles stabilized by phosphatidylcholine (PC) for application in bone

JOURNAL OF BIOMATERIALS APPLICATIONS

Authors: Karahaliloglu, Zeynep; Kilicay, Ebru

One of the most common prophylactic techniques to solve prosthetic joint infection (PJI) is incorporation of antibiotics into acrylic bone cement to prevent bacterial colonization and proliferation by providing local antibiotic delivery directly at the implant site. Further, there has been a significant concern over the efficacy of commonly used antibiotics within bone cement due to the rise in multi-drug resistant (MDR) microorganisms. Selenium is an essential trace element that has multiple beneficial effects for human health and its chemotherapeutic action is well known. It was reported that nanostructured selenium enhanced bone cell adhesion and has an increased osteoblast function. In this context, we used the selenium nanoparticles (SeNPs) to improve antibacterial and antioxidant properties of poly (methyl methacrylate) (PMMA) and tri calcium phosphate (TCP)-based bone cements, and to reduce of the infection risk caused by orthopedic implants. As another novelty of this study, we proposed phosphatidylcholine (PC) as a unique and natural stabilizer in the synthesis of selenium nanoparticles. After the structural analysis of the prepared bone cements was performed, in vitro osteointegration and antibacterial efficiency were tested using MC3T-E1 (mouse osteoblastic cell line) and SaOS-2 (human primary osteogenic sarcoma) cell lines, andS. aureus(Gram positive) andE.coli(Gram negative) strains, respectively. More importantly, PC-SeNPs-reinforced bone cements exhibited significant effect againstE. coli, comparedto S. aureusand a dose-dependent antibacterial activity against both bacterial strains tested. Meanwhile, these bone cements induced the apoptosis of SaOS-2 through increased reactive oxygen species without negatively influencing the viability of the healthy cell line. Furthermore, the obtained confocal images revealed that PC-SeNPs (103.7 +/- 0.56 nm) altered the cytoskeletal structure of SaOS-2 owing to SeNPs-induced apoptosis, when MC3T3-E1 cells showed a typical spindle-shaped morphology. Taken together, these results highlighted the potential of PC-SeNPs-doped bone cements as an effective graft material in bone applications.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket